Uncategorized Archives - Investing in science. Building Impact.

Byondis Announces Positive Topline Results of Pivotal Phase III TULIP® Study in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

by Paul Lelieveld | Jun 8, 2021 | Uncategorized

Study Meets Primary Endpoint, Confirming the ADC [Vic-]Trastuzumab Duocarmazine (SYD985) is Superior to Physician’s Choice in Delaying Disease Progression June 8 – Byondis B.V. today announced positive topline results from the Phase III TULIP® study, a...